Abstract
1472
Objectives: We compared the changes of 3'-deoxy-3'-[3H]fluorothymidine (FLT) and 2'-deoxy-2'-[3H]fluorodeoxyglucose (FDG) uptakes with cell survival and apoptosis after cisplatin treatment in lung cancer cells. Methods: Human lung cancer cell, A427 and A549 were incubated with variable concentrations of cisplatin (CDDP) (0, 2, 20, 120, 200 ug/ml) for 4 hours at 37°C, 5% CO2 in 96-well plate and then 3H-FDG and 3H-FLT were added to 1uCi/ml per well for 2h after changing the culture medium. Cellular uptake and the remains in supernatant were measured using MicroBeta (PerkinElmer, USA) and the protein quantification was estimated by BCA assay. Cell viability was evaluated to clonogenic assay and MTT assay. The aspect of apoptosis at 20ug/ml of CDDP was analysed by Annexin-V/PI assay kit (BD Biosciences, USA). Results: The uptake value of FLT and FDG in A427 was greater than A549 (FLT: 3.0 × 10-6 vs 1.8 × 10-6 cpm/media/protein, FDG: 1.9 × 10-6 vs 0.9 × 10-6 cpm/media/protein). The % uptake change by FLT and FDG were lower than the survival fraction by MTT assay and were higher than the survival fraction by clonogenic cell assay. There was difference between the uptakes of FDG and FLT at the concentration of 2, 20, 120 ug/ml. The extent of the difference was greater in A427 than in A549. At the concentration of 20 ug/ml, the % uptake of FLT and FDG were 48% and 90% in A427, and 52% and 77% in A549. The survival fractions after 4 hr incubation with CDDP were 38.3% in A427 and 53.6% in A549 by apoptosis assay. Conclusions: FLT uptake is reflecting the proliferative change more sensitively for monitoring early responses to chemotherapy than FDG in lung cancer cells.
Research Support (if any): This work was supported by a grant from the National Cancer Center (0510510-1).
- Society of Nuclear Medicine, Inc.